China Medical System's JAK1 Inhibitor Povorcitinib Receives Breakthrough Therapy Designation for Vitiligo Treatment
核心洞察
China Medical System's subsidiary Dermavon has secured licensing rights to povorcitinib, an oral JAK1 (搜索) inhibitor that received breakthrough therapy designation from China's NMPA for non-segmental vitiligo treatment.
The drug demonstrated significant improvement in total body repigmentation after 24 weeks of treatment in a Phase 2b clinical trial, with extended use showing further improvement in both total body and facial repigmentation.
Povorcitinib is currently in Phase 3 trials for multiple indications including non-segmental vitiligo, hidradenitis suppurativa, and prurigo nodularis, addressing a significant unmet need for China's estimated 8.2 million non-segmental vitiligo patients.
China Medical System Holdings Limited (搜索) announced that its subsidiary Dermavon Holdings Limited (搜索) has obtained licensing rights to povorcitinib, an innovative oral JAK1 (搜索) inhibitor that has been included in the list of Breakthrough Therapeutic Drugs by China's National Medical Products Administration (NMPA). The designation covers the proposed indication for adult patients with non-segmental vitiligo and has the potential to accelerate the drug's development and review process.
Clinical Development and Efficacy Data
Povorcitinib is a selective oral small-molecule JAK1 (搜索) inhibitor currently undergoing Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa, and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for asthma treatment is also ongoing.
The drug demonstrated significant clinical efficacy in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. In March 2023, Incyte announced that povorcitinib met the primary endpoint, showing that after 24 weeks of treatment, total body repigmentation of patients treated with povorcitinib once daily was significantly improved compared with vehicle. Extended Phase 2b trial data revealed that longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile.
Addressing Significant Unmet Medical Need
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, resulting from the loss of pigment-producing cells known as melanocytes. According to China Insights Consultancy data, approximately 10.3 million vitiligo patients exist in China, with non-segmental vitiligo patients accounting for approximately 8.2 million of these cases.
Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo.
Regulatory Progress and Commercial Strategy
In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the product in China and may consider further initiating clinical development for the treatment of skin-related diseases such as hidradenitis suppurativa and prurigo nodularis in the future.
The breakthrough therapy designation is expected to accelerate povorcitinib's development and review process in mainland China. If approved for marketing, the product has the potential to synergize with Dermavon's existing portfolio, including the commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and the innovative drug currently under New Drug Application review, ruxolitinib phosphate cream.
Licensing Agreement Details
The Group, through a subsidiary of Dermavon, entered into a Collaboration and License Agreement for povorcitinib on March 31, 2024, with Incyte. The agreement grants an exclusive license to research, develop, register and commercialize the product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries. The subsidiary also obtained a non-exclusive license to manufacture the product in the territory.
The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the territory other than Mainland China to the Group, excluding Dermavon and its subsidiaries. Povorcitinib has compound and use patents in certain countries and regions within the licensed territory.